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Abstract: Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection 
has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of 
AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS ill-
ness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature 
cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population 
coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the 
well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia. 
This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-
physiology, including associations with use of specific antiretroviral medications, and suggest screening and management 
strategies.  
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INTRODUCTION 
  The introduction of effective highly active antiretroviral 
therapy (HAART) in the mid-1990s led to a marked reduc-
tion in morbidity and mortality from human immunodefi-
ciency virus (HIV) infection [1, 2]. Increasing life-
expectancy [3], an aging population [4], and high rates of 
smoking [5] have led to concerns over the cardiovascular 
health of HIV-infected individuals in the long term. Meta-
bolic effects of HIV infection such as hypertriglyceridemia 
are long recognised [6], and side effects of HAART such as 
dyslipidemia and insulin resistance were described very soon 
after its introduction [7]. Initial concerns of increased rates 
of myocardial infarction arising as a result of dyslipidaemia 
in HIV-infected patients on antiretrovirals (ARV) [8, 9, 10] 
have been confirmed by studies such as the D:A:D study, a 
large, prospective, multi-cohort study that showed associa-
tions between exposure to antiretroviral therapy and an in-
creased risk of myocardial infarction [11]. In multivariate 
analyses, for every mmol/L increase in total cholesterol, the 
relative risk of myocardial infarction increased by a factor of 
1.26 [12]. In another analysis from D:A:D which included 
stroke, acute myocardial infarction and invasive cardiovas-
cular procedures there was a similar effect of hypercholes-
terolemia, with every mmol/L increase in total cholesterol 
associated with a relative risk of 1.11 of the combined end-
point [13]. There are little other data on associations between 
lipid profiles and other markers of vascular disease such as 
peripheral arterial disease. 
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  Additional well-established cardiovascular risk factors 
are more commonly found in HIV-infected individuals such 
as high smoking rates [5], diabetes and insulin resistance 
[14] and hypertension [15]. Also, although dyslipidemia is a 
common problem encountered in delivering care to HIV-
infected individuals, it is not the only described adverse ef-
fect of antiretroviral medications on the cardiovascular sys-
tem. HIV-infected individuals have increased carotid artery 
intermediate thickness compared to HIV-negative controls, 
and those on HAART have further disturbances in vascular 
distensibility and compliance [16]. Endothelial function is 
also abnormal in HIV-infected individuals compared to 
negative controls, with higher serum levels of markers of 
endothelial dysfunction such as soluble P-selectin, von 
Willebrand factor and others  [17]. Changes in platelet reac-
tivity among HIV-infected individuals have been reported
1, 
and increased insulin resistance and higher prevalence of 
diabetes is a well described side effect of exposure to some 
ARV [7, 18]. All of these factors likely act in combination 
with dyslipidemia to increase overall cardiovascular risk for 
those infected with HIV.  
THERAPY FOR HIV INFECTION 
  Conventional HAART consists of a combination of three 
medications drawn from three main drug classes; nucleoside 
reverse transcriptase inhibitors (NRTIs - nucleoside [or nu-
cleotide] analogues which inhibit the viral reverse tran-
                                                 
1Satchell C, Cotter A, O'Connor E, et al. A Case Control Assessment of Platelet Func-
tion in HIV-1+ and HIV-1- Individuals. Abstract 737, Sixteenth Conference on Retro-
viruses and Opportunistic Infections, Montreal, 2009. 
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scriptase (RT) enzyme) [19], non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs - which also inhibit the RT 
enzyme) and protease inhibitors (PIs - which act on the HIV 
protease)  [20]. Traditionally HAART combines two NRTIs 
with either a NNRTI, or a PI [21]. The decision on which 
dual NRTI combination or ‘backbone’ to use, and which 
agent to combine it with, is dependent on numerous factors, 
including CD4+ T-cell count, HIV viral load, potential   
toxicities, drug interactions, pill burden and viral resistance. 
PATTERNS OF DYSLIPIDEMIA IN HIV 
HIV Infection 
  Prior to the introduction of HAART, it was recognised 
that HIV infection itself caused dyslipidemia [6]. Declines in 
total cholesterol, low density lipoprotein cholesterol (LDL-
C) and high density lipoprotein cholesterol (HDL-C) have 
been shown in men who seroconverted from HIV-negative to 
HIV-positive [22]. HIV-infected, untreated patients (particu-
larly those with more advanced disease) are more likely to 
have low total, LDL-C and HDL-C and elevated serum 
triglyceride (TGs) than HIV-negative controls [23, 24, 25], 
with lower HDL-C concentrations associated with higher 
circulating HIV RNA levels and longer duration of HIV in-
fection [26, 27].  
Antiretroviral Therapies 
  A summary of the overall effects of antiretrovirals on 
serum lipids are listed in Table 1. Effective HAART sup-
presses HIV RNA to undetectable levels, allowing immune 
recovery, measured by increases in CD4+ T-cell counts, in 
the majority of patients. This is usually accompanied by 
some increases in total cholesterol and LDL-C [22, 28] 
which some have suggested may be a return to norm. How-
ever, with some PI based therapies, HDL-C levels remain 
low [22, 29], and hypertriglyceridemia may in fact worsen 
[30], giving rise to a distinctly atherogenic lipid profile  [31]. 
In contrast, initiation of NNRTI based HAART regimens has 
been shown to result in increases in HDL-C of approxi-
mately 40% depending on the agent used, with increases in 
total cholesterol, LDL-C and triglycerides also seen, al-
though the triglyceride increases are usually not as severe as 
those seen with some PIs  [32]. 
  Many ARVs have dyslipidemic properties. Use of PIs has 
been associated with hypertriglyceridemia and hypercholes-
terolemia. Ritonavir, a PI, is a potent inhibitor of the hepatic 
cytochrome P4503A4 enzyme [33] used at a low dose with 
other PIs for its ability to ‘boost’ the drug concentrations of 
the PI, resulting in increased total drug exposure and half-
life, allowing for improved dosing regimens and reduced pill 
burden [34]. In healthy volunteer studies, even when used at 
a boosting dose (100mg twice daily), exposure to ritonavir 
increased triglycerides by 26% and LDL-C by 16% after 
only 2 weeks of therapy [35]. When combined with other 
protease inhibitors such as lopinavir, serum triglycerides 
increased by 83%, free fatty acids by 30% and VLDL-C by 
33% in HIV-negative subjects after 4 weeks exposure [36]. 
Similar effects have also been seen in cohorts of HIV-
Table 1.  Overall Effects of Main Antiretrovirals on Lipid Profiles  
Currently Recommended First-Line Agents are in Bold 
Antiretroviral   Total Cholesterol  LDL-C  HDL-C  Triglycerides 
PIs (boosted) 
Lopinavir 
Atazanavir 
Fosamprenavir 
Saquinavir 
Darunavir  
Tipranavir 
NNRTIs 
Efavirenz 
Nevirapine 
NRTIs 
Tenofovir 
Abacavir 
Lamivudine 
Zidovudine 
Stavudine 
CCR5 Inhibitors 
Maraviroc 
Integrase Inhibitors 
Raltegravir 
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infected patients treated with PIs, including newer drugs 
such as tipranavir [29, 37, 38]. Induction of dyslipidaemia 
does not occur with all PIs however. Atazanavir is an 
azapeptide PI with relatively few effects on serum lipids 
[39], while other newer PIs such as darunavir have also been 
shown to induce less dyslipidaemia [40].  
  Although NNRTIs induce less dyslipidemia than PIs it 
does appear that efavirenz, one of two commonly prescribed 
NNRTIs, has a deleterious effect on lipids when compared to 
the other commonly used NNRTI, nevirapine. The 2NN 
study compared HAART comprising efavirenz, nevirapine 
or both in combination with 2 NRTI (stavudine and lami-
vudine) and demonstrated greater increases in triglycerides 
in the efavirenz arm compared to the nevirapine arm (49% 
versus 20% at 48 weeks) [41]. In addition, the AIDS Clinical 
Trials Group (ACTG) 5142 trial, comparing therapy with 
lopinavir (PI) or efavirenz (NNRTI) or both with 2 NRTI, 
demonstrated significant increases in serum triglycerides and 
total cholesterol in both arms. The combination of lopinavir 
and efavirenz led to greater increases in serum triglycerides, 
non-HDL-C, and HDL-C than with either agent alone. Be-
tween lopinavir and efavirenz there was no significant dif-
ference in cholesterol levels, and only triglycerides were 
significantly higher in the lopinavir arm [32]. In the Swiss 
HIV Cohort, triglycerides tended to decrease in those treated 
with nevirapine but increase with efavirenz [42]. Overall, 
these data point to significant potential for efavirenz-induced 
dyslipidaemia, with increases in total cholesterol similar to 
some PI, but triglyceride increases that are less than ob-
served with use of some PI. 
  Use of NRTI is not free of dyslipidaemia. Use of the 
NRTI stavudine has been associated with a worse lipid pro-
file than the nucleotide reverse transcriptase inhibitor 
(NtRTI) tenofovir, with significantly larger increases in total 
cholesterol, LDL-C and triglycerides [43]. Similar effects 
were seen when tenofovir was compared to zidovudine, with 
significantly smaller increases in total cholesterol and LDL-
C observed with tenofovir use [44]. It is for reasons of tox-
icities such as these that tenofovir and abacavir are now the 
preferred first line NRTIs compared to zidovudine or sta-
vudine [21]. Recent data from the ACTG 5202 study in 
which abacavir-containing HAART was compared to teno-
fovir-containing HAART suggested that abacavir use was 
associated with significantly greater increases in median 
triglycerides (25mg/dl vs 3 mg/dl) and total cholesterol 
(34mg/dl vs 26mg/dl) than tenofovir at 48 weeks
2. Similar 
results were observed in the HEAT study, which also com-
pared abacavir and tenofovir-containing HAART in treat-
ment-naïve patients; those on abacavir had greater increases 
in serum triglycerides (64mg/dl vs 38 mg/dl) and total cho-
lesterol (32 mg/dl vs 23mg/dl) at 48 weeks
3, though the dif-
ference between arms was less at 96 weeks [45]. 
                                                 
2Sax P, Tierney C, Collier AC, et al. ACTG 5202: shorter time to virologic failure (VF) 
with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part 
of combination therapy in treatment-naïve subjects with screening HIV RNA >100,000 
c/mL. Abstract THAB0303, XVII International AIDS Conference, Mexico City, 2008. 
3Smith K, Fine D, Patel P, et al. Efficacy and Safety of Abacavir/Lamivudine Com-
pared to Tenofovir/Emtricitabine in Combination with Once-daily Lopinavir/Ritonavir 
through 48 Weeks in the HEAT Study. Abstract 774, Fifteenth Conference on Retrovi-
ruses and Opportunistic Infections, Boston, 2008. 
  Although these data point to dyslipidaemia induced by 
ARV from all of the three commonly used drug classes, not 
all patients respond similarly to antiretroviral regimens 
(ARV). Cohorts of treatment experienced patients tend to 
have had more exposure to various classes of ARVs and 
have greater adverse effects compared to treatment naïve 
patients. For example, in the ARTEMIS trial, treatment na-
ïve patients started on darunavir at 96 weeks had relatively 
small (12-15%) increases in total cholesterol, LDL-C and 
triglycerides [40]. Contrast this to the POWER studies, 
which used darunavir in heavily pretreated patients, where 
15% of patients had TG levels of greater than 8.4mmol/L 
(744mg/dL) [46]. 
Metabolic Syndrome and HIV-Associated Lipodystrophy 
  A possible explanation for the differences in dyslipidae-
mia upon HAART initiation observed in antiretroviral naïve 
versus heavily pre-treated HIV-infected patients is the 
changes in lipid metabolism induced by medium to long 
term exposure to antiretroviral therapy. While direct dyslipi-
demia induced by protease inhibitors can develop rapidly, 
other more chronic metabolic changes affecting lipid me-
tabolism can occur with HAART. Shortly after the introduc-
tion of combination antiretroviral therapy, a syndrome of 
subcutaneous lipoatrophy, central adiposity, dyslipidemia, 
and insulin resistance, termed HIV-associated lipodystrophy 
(HIVLD) was noted [7]. This was initially associated with PI 
exposure [7], but subsequently exposure to NRTIs [47], par-
ticularly thymidine analogue NRTIs (tNRTIs) such as sta-
vudine [48] and zidovudine [49] were also recognised as 
being central to the development of this syndrome. Com-
pared to HIV-infected controls without lipodystrophy, indi-
viduals with HIVLD tend to have higher total cholesterol, 
total cholesterol:HDL ratios, LDL-C and triglyceride levels 
[50, 51]. 
  In addition to HIVLD, in the general population there is 
concern about the increasing prevalence of the metabolic 
syndrome among HIV infected individuals. The pattern of 
abdominal obesity, low HDL-C, high triglycerides, and insu-
lin resistance, all seen in HIVLD, are also components of the 
metabolic syndrome [52] . The prevalence of the metabolic 
syndrome in HIV-infected populations has been reported at 
4.4% at enrolment in the D:A:D cohort [53], 17-25% in other 
studies, and as with the general population, prevalence in-
creases with age and BMI [54, 55, 56]. However, the most 
common features present in HIV-infected individuals are 
hypertriglyceridemia and low HDL-C [53, 54] and studies 
that have matched patients for age and BMI have estimated 
the prevalence of the metabolic syndrome to be similar 
among HIV-infected and HIV negative individuals [54, 55].  
PATHOPHYSIOLOGY OF DYSLIPIDEMIA IN HIV 
HIV Infection 
  Hypertriglyceridemia in untreated HIV-infected patients 
may be a response to a systemic inflammatory response 
against persistent viral infection. TG concentrations, and TG 
clearance time in untreated HIV-infected patients have been 
shown to correlate with serum interferon-alpha (IFN-) [23], 
which is overproduced in HIV infection [57]. In these un-
treated patients the activity of lipoprotein lipase (LPL) and 
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the circulation, are decreased compared to controls. Treat-
ment of hepatocytes in vitro with IFN- (and other cytokines 
such as Il-1) causes increases in lipogenesis [58], and hepatic 
lipogenesis  in vivo is higher in HIV-infected individuals 
[59]. In hepatitis C virus (HCV) infected individuals receiv-
ing IFN- therapy hypertriglyceridemia combined with low 
HDL-C levels have also been reported [60, 61], with levels 
returning to normal upon cessation of IFN- therapy. 
  The activity of cholesterol ester transfer protein (CETP), 
which transfers cholesterol esters from HDL-C to apolipo-
protein-B containing proteins [62], is elevated in HIV infec-
tion, and its activity correlates inversely with serum HDL 
concentrations [63]. This may help explain why HDL-C lev-
els are lower in HIV infection. Although the reason for ele-
vated CETP activity is still to be determined, CETP func-
tions more efficiently in the setting of high TG levels [64], 
and this could help explain the increased activity in HIV-
infected patients. 
Antiretroviral Therapies 
Direct Effect 
  PIs affect different tissues to cause dyslipidemia. In the 
liver of mice exposed to PI, excess fatty acid synthesis and 
hepatic steatosis occur after ritonavir exposure, which is as-
sociated with intra-nuclear accumulation of sterol response 
element binding proteins (SREBP), a nuclear transcription 
factor important for regulation of expression of many lipid 
metabolism genes [65, 66]. This effect has been replicated in 
hepatocytes in vitro, with an increase in SREBP-1 nuclear 
localistion [67]. Also in the liver, PIs appear to inhibit the 
proteasomal degradation of pre-secretory apolipoprotein B 
(the protein component of LDL particles) in cultured hepato-
cytes  [68]. Inhibition of proteosomal degradation of SREBP 
could also explain its accumulation in hepatic nuclei.  
  An interesting finding which points towards a hepatic 
cause of dyslipidemia is the fact that hepatitis C virus (HCV) 
co-infection appears to protect against the development of 
HAART-associated dyslipidemia [69-71]. This may be due to 
alterations in hepatocyte lipid secretion – mono-infection 
with HCV genotype 3a is associated with a lower serum cho-
lesterol but a marked increase in hepatic steatosis [72]. 
  The effect of PIs in adipose tissue is different to their 
effect in liver. In adipocytes, PIs inhibit lipolysis by impair-
ing LPL activity, which impairs TG uptake into adipocytes, 
which may contribute to elevated plasma TG levels [73]. PIs 
also inhibit SREBP-1 nuclear localisation in adipocytes [74], 
which leads to decreased adipocyte differentiation and which 
may also inhibit the ability of adipose tissue to store lipids 
removed from the circulation. In adipocytes PIs have also 
been shown to reduce expression of peroxisome proliferator-
activated receptor gamma (PPAR) [75], an nuclear receptor 
important for adipocyte differentiation. As PPAR is a tran-
scriptional target of SREBP-1, impaired nuclear localisation 
of SREBP-1 in adipose tissue may contribute to reduced 
PPAR activity. 
Indirect Effect 
  At a cellular level, individuals with HIVLD have atrophic 
subcutaneous fat with smaller adipocytes, macrophage infil-
tration and evidence of adipocyte apoptosis [76]. It is known 
that tNRTIs can accumulate within adipocytes [77]. Adipo-
cytes from patients exposed to tNRTIs demonstrate mito-
chondrial dysfunction, manifested by depletion of mitochon-
drial DNA (mtDNA) [76, 78] and reduced mitochondrial 
RNA (mtRNA) expression [79]. This is felt to be due in part 
to the ability of tNRTIs to inhibit DNA polymerase-, the 
enzyme responsible for replication of mtDNA [80]. Com-
pared to protease inhibitors, which induce dyslipidemia 
within a short period of time, the effect of NRTIs on serum 
lipids takes longer. 6 weeks exposure to tNRTIs did not sig-
nificantly alter lipid parameters in healthy volunteers, though 
a reduction in mtRNA expression were seen as early as 2 
weeks, without reductions in mtDNA  [81]. As with PIs, a 
downregulation of PPAR expression in adipose tissue was 
also observed. The effect of this downregulation is potent as 
it cannot be overcome with the PPAR agonist rosiglitazone 
in the presence of ongoing tNRTI use [79]. These molecular 
effects may explain how NRTIs can inhibit preadipocyte 
differentiation  [82], reduce triglyceride accumulation [83] 
and increase adipocyte apoptosis [84] in vitro. 
  As well as their effects on lipid metabolism outlined 
above, PIs also affect adipose tissue. PIs can accumulate   
in adipocytes [77], and ritonavir, lopinavir and saquinavir 
inhibit adipocyte differentiation [85], an effect not seen   
with atazanavir, a PI associated with less dyslipidaemia   
[86]. Nelfinavir has also been shown to induce adipocyte 
apoptosis [87]. 
  The ultimate result of abnormally functioning subcutane-
ous adipose tissue is reduced storage capacity for circulating 
lipids resulting in increased circulating free fatty acids  [88], 
reduced adiponectin secretion [89], and lipid accumulation in 
non-adipose tissues such as liver (hepatic steatosis [90] and 
hepatic triglyceride accumulation [91]). This, combined with 
the effects of PIs on lipid metabolism as mentioned in the 
previous section, likely underlie the hypertriglyceridemia 
and hypercholesterolemia observed in HIVLD. Clinical stud-
ies have shown that a combination of a PI with NRTIs are a 
greater risk than PIs alone for the development of lipodys-
trophy and dyslipidemia [92]. 
MANAGEMENT STRATEGIES 
  Although dyslipidaemia in HIV-infected patients is 
common, not all patients with dyslipidemia require lipid 
lowering therapy. The goal of therapy, as in the HIV nega-
tive population, is to reduce an individual’s cardiovascular 
risk. Therefore treatment of HIV-associated dyslipidemia 
should be an integral part of a general attempt to improve 
cardiovascular health, with advice on diet and exercise, 
smoking cessation, management of hypertension and diabe-
tes where present, and the use of anti-platelet agents where 
warranted. 
  Despite this, in a recent retrospective review, HIV-
infected veterans in the USA who met NCEP/ATPIII guide-
lines for dyslipidemia were half as likely to be receiving 
lipid lowering therapies as HIV-negative controls [93]. HIV-
infected patients should be screening for dyslipidemia at 
HIV diagnosis, annually, and upon starting HAART. An 
individual’s cardiovascular risk should be assessed by stan-
dardised scoring systems such as the Framingham or Joint 
British Societies score, and treatment instituted for those Dyslipidemia in HIV Infection  The Open Cardiovascular Medicine Journal, 2011, Volume 5    53 
with previous cardiovascular disease or a high (>20% in 10 
year) risk of cardiovascular disease (Fig. 1). 
  Current European Aids Clinical Society (EACS) guide-
lines recommend target LDL-C levels dependent on an esti-
mated 10 year cardiovascular risk. The Infectious Diseases 
Society of America guidelines use a similar estimate of risk. 
These are summarised in Table 2. 
  EACS guidelines recommend only treating severe iso-
lated hypertriglyceridemia (TGs >10mmol/L), or combined 
hyperlipidemia (LDL-C elevated and TG 2.3-10mmol/L) 
with lipid lowering therapy, while treating isolated hyper-
triglyceridemia with TG<10mmol/L with dietary and life-
style advice. IDSA recommend treatment of isolated 
TGs>5.6mmol/L (500mg/dL) or elevated LDL-C and TGs of 
2.2-5.6mmol/L (200-500mg/dL). 
  The treatment options available for the management of 
dyslipidemia in HIV-infection are similar to those in the 
general population; dietary and lifestyle modification and the 
use of lipid lowering medications. An additional option in 
those on HAART is the ability to switch antiretrovirals away 
from those that may exacerbate the dyslipidemia. Although 
all these options have been studied in HIV-associated dyslip-
idemia, many studies are open-label, few are randomised and 
even fewer placebo-controlled. While many of these studies 
have shown beneficial effects of switching HAART compo-
nents or lipid lowering therapy on dyslipidemia, there are no 
data available on the impact of these effects on cardiovascu-
lar disease endpoint and any perceived benefit is derived 
from corresponding beneficial effects on CVD of lipid   
lowering in the general population. 
Dietary / Lifestyle Modification 
  As in the management of dyslipidemia in HIV-negative 
subjects, counselling on ‘therapeutic lifestyle changes’ such 
as reducing fat and cholesterol intake, increasing physical 
activity, weight reduction and adjusting diet to reduce LDL-
C are also important components of managing HIV-
associated dyslipidemia [94], although the data on a benefi-
cial result are inconsistent. Despite similar caloric intake, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Screening and treatment algorithm. 
Table 2.  LDL-C Treatment Goal Recommendations 
Recommending Group  Risk <10%  Risk 10-20%  Risk >20% Previous CV Disease Diabetes 
EACS  <5.0mmol/L (<190mg/dL)  <4.0mmol/L (<155mg/dL)  <3.0mmol/L (<115mg/dL) 
IDSA/ACTG  <4.1mmol/L (<160mg/dL)  <3.3mmol/L (<130mg/dL)  <2.6mmol/L (<100mg/dL) 
Screen for dyslipidemia
At diagnosis
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On starting HAART
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Smoking cessation
Treat hypertension / diabetes
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Lipid Lowering Therapy Antiretroviral Switch
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HIV-infected individuals have been shown to ingest more 
saturated fat than HIV-negative matched controls, and die-
tary saturated fat intake correlates with serum triglyceride 
concentrations [95]. In an early study in PI-treated patients 
with dyslipidemia, a diet and exercise program led to an 11% 
reduction in total-C, and a 21% reduction in TG  [96]. How-
ever, in a study examining the effect of fish oil on serum 
lipids in HAART treated subjects with hypertriglyceridemia, 
those randomised to dietary and exercise counselling   
alone only reduced TG levels by 6%, with no change in LDL 
cholesterol at 16 weeks despite decreased caloric and total 
fat intake [97]. In another study of individuals with hyper-
triglyceridemia on HAART, only 4 of 49 individuals achieved 
normal TG levels at any stage within an 18 month period 
with diet and exercise alone  [98]. It is therefore unlikely  
that lifestyle modifications alone will suffice in correcting 
HAART-induced dyslipidemia in the presence of ongoing 
exposure to the antiretrovirals precipitating the problem. 
Switch Strategies 
  An approach available to some HAART-treated patients 
with dyslipidemia is to switch away from the presumed of-
fending agent to another ARV with less propensity to induce 
dyslipidemia [99]. Studies examining this strategy are sum-
marised in Table 3. These options should only be considered 
when there is a viable alternate antiretroviral agent or regi-
men, the new regimen is likely to induce less dyslipidemia 
than the original and is likely to possess similar or enhanced 
antiretroviral potency compared to the original regimen. At 
all times, maintenance of an effective ARV regimen capable 
of durable viral suppression is of paramount importance. 
Switching therapy needs careful discussion with patients 
about potential risks and benefits of changing what may be a 
virologically successful ARV regimen. 
PI Switches 
Within Class Switching 
  Switching from one PI to another has the advantage of 
maintaining the same class of drug whilst preserving future 
treatment options. Atazanavir is a potent PI with once-daily 
dosing and relatively favourable effects on serum lipids [39], 
making it an attractive option to switch to from other PIs. 
The need to “boost” atazanavir by using boosting doses of 
ritonavir [100], may reduce the beneficial effects on lipids. 
However, even when ritonavir-boosted, atazanavir induces 
less dyslipidemia than other boosted PIs [101], with the pos-
sible exception of the newer agent darunavir, which appears 
to have similar effects on lipid parameters to atazanavir in 
HIV-negative individuals [102]. 
  Many studies examining switching to atazanavir did not 
actively recruit patients with dyslipidemia [103, 104, 105, 
106]. However there appears to be a consistent reduction in 
triglycerides and cholesterol among those who switched 
compared to those who remained on other PIs (Table 3). 
This appears to hold true even for those who switch to 
boosted atazanavir, though the margin of reduction in lipids 
is smaller [104]. Atazanavir can also be used ‘un-boosted’. 
One study that examined the effect of switching to un-
boosted atazanavir in patients with hypercholesterolemia   
demonstrated reductions in triglycerides and total cholesterol 
without concomitant lipid-lowering therapy [107]. However 
only 37% of patients achieved LDL-C 130mg/dL. 
Switching to a Different ARV Class 
  Until recently, the options for switching away from pro-
tease inhibitors had been confined to NRTI or NNRTI 
switches. Switching a PI to a NNRTI such as efavirenz or 
nevirapine makes virological sense, as the combination of 2 
NRTIs and one NNRTI is a well studied and effective antivi-
ral combination [99]. However NNRTI have a low genetic 
barrier to resistance, with only one mutation required to in-
duce high level resistance, raising concerns regarding the 
efficacy of this approach, particularly in patients who have 
been previously exposed to NNRTIs. It appears that switch-
ing to nevirapine compared to efavirenz has a better effect on 
lipids  [108, 109]. Studies have shown that switching a PI to 
nevirapine has a minor effect on lipids and is virologically 
safe [109, 110, 111], though the magnitude of the lipid-
lowering effect has been shown to be inferior to lipid lower-
ing therapy alone [109].  
  Switching a PI to a NRTI such as abacavir, leaving pa-
tients on a triple combination of NRTIs, while well-tolerated 
and beneficial from a lipid perspective, has been shown to be 
virologically inferior to conventional HAART comprising 
drugs from more than one drug class [112, 113] and is now 
not generally recommended. 
NRTI Switches 
  As previously discussed, thymidine analogue NRTIs 
(tNRTIs) are associated with subcutaneous fat loss, adipose 
tissue dysfunction, and increases in cholesterol and triglyc-
erides (HIV-associated lipodystrophy). Switching away from 
tNRTIs to other NRTIs such as abacavir and tenofovir has 
been investigated as a therapeutic option for HIVLD and 
have resulted in both increases in subcutaneous fat [114] and 
improvements in dyslipidemia [115]. 
  Switching from tNRTI to tenofovir appears to have more 
favourable effects on lipids than switching from tNRTI to 
abacavir, though the overall lipid improvements are often 
slight [115, 116, 117]. In one comparative randomised trial, 
switching from stavudine to tenofovir rather than abacavir 
resulted in significantly greater improvements in total cho-
lesterol (median reduction of 0.45mmol/L) and LDL-C (me-
dian reduction of 0.25 mmol/L) [114]. Similarly in the BI-
COMBO study, in which patients were randomised to switch 
from any NRTI to either tenofovir or abacavir, those switch-
ing to tenofovir had lower fasting total cholesterol, LDL-C, 
HDL-C and triglycerides at week 48 than those switching to 
abacavir [118]. However the between group differences were 
relatively small and there was no difference in the use of 
lipid lowering agents at the end of the study. One study has 
examined dose reduction of stavudine compared to switching 
to tenofovir. Despite most patients having normal lipids at 
baseline, switching to tenofovir resulted in greater lipid im-
provements than stavudine dose reduction [119]. The 
SWEET study examined the effect of switching from   
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Table 3.  Antiretroviral Switch Studies and Effect on Lipids 
Study Patient  Group  N  Switch 
From 
Switch to (N)  Weeks  LLT* in use  Outcome  Notes 
PI Switch 
Sension et al. 
[107] 
PI based HAART 
LDL-
C130mg/dL 
246 PI  ATV 
Immediate vs 
delayed 
48 No  35% TG 
18% LDL-C 
37% achieved  
LDL-C130mg/dl 
Tenofovir not used 
Unboosted atazanavir 
Soriano et al. 
[104] 
(SLOAT) 
 
LPV/r based 
HAART 
 
189 
 
LPV/r ATV(49)  or 
ATV/r (53) 
vs no switch (87) 
48 Yes 
(More in 
LPV/r arm) 
9.5% total-C (0.2% LPV/R) 
43.7% TG (3.4% LPV/R) 
No significant change LDL-C 
4% ATV LDL-C160mg/dL 
16% LPV/r LDL-C160mg/dL 
 
ATV/r if tenofovir in NRTI backbone 
Previous PI failure permitted 
12 virologic failures on ATV – all 
had previously failed PI 
21.9% TG ,  
6.2% total-C ATV/r (boosted) 
48.7 TG, 12.9% ATV (unboosted) 
Gatell et al. 
[103] 
(SWAN) 
PI-based HAART 
 
419  PI  ATV (252) or 
ATV/r (26) 
or no switch (141) 
48 Yes  33% TG 
18% total-C 
12% LDL-C 
Previous PI failure not permitted 
ATV/r if tenofovir in NRTI backbone 
Nguyen et al. 
[105] 
PI-based HAART 
 
36 PI  ATV/r  24  Yes  23% TG 
9% total-C 
13% LDL-C 
Retrospective review 
47% patients met NCEP III  
guidelines at 6months 
Wood et al. 
[106] 
 
NFV / d4T / 3TC  63 NFV  ATV    24  Yes  25% TG 
16% total-C 
20% LDL-C 
 
NNRTI Switch 
Negredo et al. 
[110] 
 
PI-based HAART 
 
77 
 
PI NVP  (26) 
EFV (25) 
Vs no switch (26) 
52 Yes  21% TG, 10% total-C NVP 
group 
 
No significant change EFV group or 
no switch group 
Estrada et al. 
[108] 
 
PI-based HAART 
Lipodystrophy 
28  PI  EFV  48  Yes  No significant change  No improvement lipodystrophy 
Calza et al. 
[109] 
 
PI-based HAART  
TGs 200mg/dL 
Total-C 
>250mg/dL 
130 PI  NVP  (29) 
EFV (34) 
Vs lipid  
lowering (67) 
52 No   
(comparator) 
25% TG, 27% total-C NVP 
group 
9.4% TG, 24% total-C EFV 
group 
 
Lipid lowering therapies  
(statin / fibrate) better than switch 
Martinez et al. 
[112] 
 
PI-based HAART 
 
460 PI  NVP  (155) 
EFV (156) 
ABC (162) 
52  Yes  No difference in median TG 
levels 
Total-C lower in ABC group 
Fewer patients in ABC group: 
with TG 400mg/dL  
with total-C 240mg/dL  
Higher virologic failure  
in abacavir group 
Martinez et al. 
[150] 
PI based HAART  
Lipodystrophy 
20 PI  EFV  24  Yes  25% TG 
No change total-C 
No improvement lipodystrophy 
Carr et al. 
[151] 
PI-based HAART 
Lipodystrophy 
81 PI  NVP+ABC  (49) 
+hydroxyurea 
+adefovir 
vs no switch (32) 
24 Yes  Switch  group: 
34.6% TG 
25% total-C 
Significant between group difference 
in total-C and TG  
37% discontinuation rate in switch 
group at 24 weeks 
Petit et al. 
[111] 
PI-based HAART 
 
55 PI  NVP  24  Yes  17.8% TG 
No change in total cholesterol 
16.8% HDL-C 
Significant change in  
TG only seen in men 
Men had higher TG at baseline 
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Study Patient  Group  N  Switch 
From 
Switch to (N)  Weeks  LLT* in use  Outcome  Notes 
NRTI Switch 
Llibre et al. 
[116] 
 
On d4T with 
toxicity 
(172 with  
dyslipidemia) 
352 d4T  Tenofovir 
 
48 Yes  In patients with baseline  
dyslipidemia: 
26.9% TG 
14.1% total-C 
17.8% LDL-C 
77% of patients had lipodystrophy 
 
Madruga et al. 
[115] 
d4T+3TC+EFV 85  d4T  Tenofovir  144  Yes  78mg/dL TG 
22mg/dL total-C 
 
Ananworanich 
et al.  [117] 
d4T+ddI+SQV/r 35  d4T 
ddI 
Tenofovir  
+ Lamivudine 
48 Yes  17% TG 
4.5% total-C 
6.7% LDL-C 
Some improvement in lipoatrophy 
Martin et al. 
[152] 
tNRTI-containing 
HAART 
Lipoatrophy 
85  d4T/ 
AZT 
Abacavir (42) 
vs no switch 
104 Yes  No improvement in  
lipid parameters 
Some improvement in lipoatrophy 
Moyle et al. 
[114] 
 
tNRTI-containing 
HAART 
Lipoatrophy 
105  d4T/ 
AZT 
Tenofovir (52) 
Abacavir (53) 
48 Yes  Tenofovir: 
8% total-C, 16.5% TG,  
7.5% LDL-C 
Abacavir 
3.9% total-C, 4.1%TG, 3% 
LDL-C 
Significant differences in total-C and 
LDL-C between arms 
Both arms had increase in limb fat 
Small rises in cholesterol in both 
arms when switching from AZT 
Schwede et al. 
[153] 
d4T containing 
HAART 
66 d4T  Tenofovir  72 
(mean) 
Yes  36mg/dL total-C 
No significant TG at 72 weeks 
Retrospective analysis 
Initial 84mg/dL decrease in TGs at 
12 weeks 
Milinkovic  
et al.  [119] 
d4T containing 
HAART 
Lipoatrophy 
58 d4T  Tenofovir (17) 
Low dose d4T (19) 
vs continue d4T (22) 
24 None  used  Low dose d4T 
8% TG 0.6% total-C 
Tenofovir 
28.7% TG 15.6% total-C 
Most patients had normal lipids at 
baseline 
Martinez et al. 
[118] 
(BICOMBO) 
HAART with 2 
NRTIs 
333 NRTI  Tenofovir / FTC 
(166) 
Abacavir / 3TC 
(167) 
48 Yes  Total-C, LDL-C, HDL-C, TGs 
lower in tenofovir arm 
Lipid lowering agent use similar in 
both arms 
Fisher et al.  
[120] 
(SWEET) 
AZT with 
3TC+EFV 
234 AZT  Tenofovir (117) 
vs no switch (117) 
48 Yes  Greater decrease in total-C, TGs 
in tenofovir arm at week 24 
No significant difference at week 48 
Reduction greatest in those with 
higher levels at baseline 
*LLT = lipid lowering therapy. 
 
had lower total cholesterol and triglycerides at 24 weeks 
(with the greatest reductions occurring in those with the 
highest baseline values), there were no statistically signifi-
cant between group differences at 48 weeks between each 
arm  [120]. 
Treatment Interruption 
  Cessation of HAART has been proposed as a therapeutic 
option in dyslipidemia, and does result in improvements in 
TG, total-C and LDL-C even after a short period of time 
[121]. However, clinical studies have shown excess morbid-
ity and mortality, including increased major cardiovascular, 
renal and hepatic events in those undergoing treatment inter-
ruption [122]. As a result this strategy should not be consid-
ered as therapy for dyslipidemia.  
Lipid Lowering Therapies 
  Many lipid lowering therapies have been investigated in 
HIV infection (summarised in Table 4). The treatment of 
dyslipidemia in HIV infection is often complicated by poten-
tial drug interactions between ARV and lipid-lowering 
medications. In addition, other medications used in the 
treatment of HIV-infection such as macrolide antibiotics 
[123], azole antifungals [124] or the rifamycin antimycobac-
terials [125] may also have significant interactions with 
lipid-lowering agents. 
Fish Oils 
  Fish oils, rich in omega-3 fatty acids, can help lower 
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Table 4.  Trials of Lipid Lowering Agents in HIV Infection 
Study Patient  Group  N  Intervention (N) Followup  Outcome    Notes 
Fish Oils 
Wohl et al. 
[97] 
On HAART 
TG200mg/dl 
52  3g fish oil / day (26) 
vs diet and exercise alone 
16  19.5% TG 
(5.7% TG in diet/ 
exercise) 
No significant difference at week 16 
Approximately 20% increase  
LDL cholesterol both arms 
Gerber et al.  
[126]  
On HAART  
TG400mg/dl, LDL-
C160mg/dL 
100  6g fish oil / day (50) 
vs fenofibrate 
8  46% TG 
37% LDL-C 
8.5% achieved TG 200mg/dL 
Addition of fenofibrate allowed 22.1% to achieve 
TG 200mg/dL at 18 weeks 
Manfredi et al.  
[98] 
On HAART 
TG 200-500mg/dl on 2 
occasions 
156  2g polyunsaturated ethyl esters of 
n-3 fatty acids / day (54) 
vs fibrates vs diet and exercise 
72  11.6% TG 
 
25.9% achieved target TG 172mg/dL at any stage 
Superior to diet and exercise alone 
Fibrates 
Palacios et al.  
[129] 
On HAART 
TG400mg/dl 
20 Fenofibrate  200mg/day  24  53.6% TG 
14.1% total-C 
70% achieved TG400mg/dl 
Badiou et al. 
[127] 
On HAART 
TG175mg/dL 
36  Fenofibrate 200mg/day (18) 
vs Vitamin E 
12  40% TG 
14% total-C 
15% HDL-C 
 
Aberg et al. 
[131] 
On HAART 
Combined dyslipidemia 
88  Fenofibrate 200mg/day  12    1% achieved NCEP guidelines on fenofibrate alone 
Gerber et al. 
[126]  
On HAART 
TG400mg/dl, LDL-
C160mg/dL 
100  Fenofibrate 160mg/day (50) 
vs fish oil 
8  58% TG 
46% LDL-C 
10% total-C 
16.7% achieved TG 200mg/dL 
Addition of fish oil allowed 22.1% to achieve TG 
200mg/dL at 18 weeks 
Manfredi  
et al.  [98] 
On HAART 
TG 200-500mg/dl on 2 
occasions 
156 Bezafibrate / Gemfibrozil / 
Fenofibrate (53) 
72  34% achieved target 
TG 172mg/dL  
at any stage 
Superior to fish oil & diet and exercise 
Miller et al. 
[154] 
On PI-containing HAART 
TG263mg/dL 
37  Gemfibrozil 600mg/day (17) 
Vs placebo 
12  100mg/dL TG  Did not achieve significance 
Calza et al. 
[128] 
On PI-containing HAART 
TG300mg/dl  
+/- total-C 290mg/dl 
106 Bezafibrate 400mg / day (25) 
Gemfibrozil 600mg / day (22) 
Fenofibrate 200mg / day (22)  
vs pravastatin / fluvastatin 
52  40.7% TG 
21.9% total-C 
Statins / fibrates achieved similar reductions 
Calza et al. 
[109] 
On PI-containing HAART 
TG200mg/dl 
Total-C 250mg/dl 
130 Bezafibrate 400mg/day (31) 
Vs NNRTI switch 
Vs pravastatin 
52  46.6% TG 
37.6% total-C 
Statins / fibrates similar efficacy 
Statin / fibrates superior to NNRTI switch 
Statins 
Calza et al. 
[132] 
On PI-containing HAART 
Total-C 240mg/dL 
(TG 500mg/dl excluded) 
16 Rosuvastatin  10mg/day  24  30.1% TG 
21% total-C 
22.4% LDL-C 
28.5% HDL-C 
 
Bonnet et al. 
[136] 
On PI-containing HAART 
Total-C 210mg/dL 
LDL-C130mg/dL 
21  Pravastatin 40mg/day (12) 
Vs placebo 
12  No change in TG 
23% total-C 
24% LDL-C 
 
Mallon et al. 
[134] 
On PI-containing HAART 
Total-C 253mg/dL 
  Pravastatin 40mg/day (16) 
Vs placebo 
12 Greater  TWAUC 
change in  
cholesterol in 
pravastatin arm 
No difference in time weighted-change  
in cholesterol between arms 
Increased limb fat in pravastatin arm 
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Study Patient  Group  N  Intervention (N) Followup  Outcome    Notes 
Statins 
Calza et al. 
[128] 
On PI-containing HAART 
TG300mg/dl  
+/- total-C 290mg/dl 
106  Pravastatin 20mg/day (19) 
Fluvastatin 20mg/day (18) 
Vs fibrates 
52  36.1% TG 
26.9% total-C 
Statins / fibrates achieved similar reductions 
Calza et al. 
[109] 
On PI-containing HAART 
TG200mg/dl 
Total-c 250mg/dl 
130  Pravastatin 20mg/day (36) 
Vs NNRTI switch 
Vs bezafibrate 
52  41.2% TG 
45.8% total-C 
Statins / fibrates similar efficacy 
Statin / fibrates superior to NNRTI switch 
Palacios  
et al. [130] 
On HAART 
Total-C 240mg/dl 
20 Atorvastatin  10mg/day 
 
24 
 
40% TG 
27% total-C 
37% LDL-C 
 
Baldini et al. 
[133] 
On HAART 
Hyperlipidemia 
19 Pravastatin  20mg/day 
 
8  37% TG 
19% total-C 
 
Niacin 
Gerber et al. 
[143] 
On HAART 
TG200mg/dL  
+/- LDL130mg/dL 
14  ER-Niacin up to 2000mg/day  14  34% TG 
14% total-C 
 
Concern over glucose intolerance 
Dube et al. 
[144] 
On HAART 
TG200mg/dL  
non-HDL-C180mg/dl 
33  ER-Niacin up to 2000mg/day  48  32% TG 
3% total-C 
 
Transient increases in insulin resistance 
Ezetimibe 
Wohl et al. 
[141] 
On HAART 
LDL-C 75mg/dL, 
TG800mg/dL 
48 Ezetimibe  10mg/day  6  5.3% total-C 
TG unchanged 
 
Negredo  
et al. [142] 
On / off HAART 
LDL-C130mg/dL  
despite pravastatin 
20mg/day 
19  Ezetimibe 10mg/day  
+ Pravastatin 20mg/day 
 
24 Significant  in LDL-
C, total-C 
Significant HDL-C 
No change TG 
61.5% achieved LDL-C130mg/dl  
 
 
They are generally well tolerated and have few side-effects. 
Although a randomised study of 3g of fish oil daily together 
with diet and exercise resulted in a 19.5% mean decrease in 
TGs at 16 weeks (though this was not statistically significant 
compared to diet and exercise alone), LDL-C concentrations 
actually increased by 22% [97]. In a further study (ACTG 
5186), comparing 6g of fish oil per day to fenofibrate in 
HIV–infected patients on HAART with isolated severe hy-
pertriglyceridemia, those on fish oil experienced a 46% re-
duction in median TG at 8 weeks, but only 8.5% achieved 
TG levels 200mg/dL and LDL-C concentrations increased. 
Combining fish oil with fenofibrate achieved normal TG 
levels in 22% of patients [126]. Treatment of HIV-infected 
patients with moderate HAART-related hypertriglyceridemia 
with polyunsaturated ethyl esters of n-3 fatty acids resulted 
in a 11.6% reduction in TG levels at 18 months, with 25.9% 
of patients achieving normal TG levels at some stage over 
the 18 months follow-up [98]. Given the rises in LDL-C ob-
served in these studies, it is unclear if use of fish oils in this 
clinical setting will have an overall clinical benefit in terms 
of cardiovascular risk reduction. 
Fibrates 
  Fibrates are an attractive therapeutic option in HIV-
infected patients, as hypertriglyceridemia is common and 
fibrates lack significant pharmacologic interactions with 
ARV. Fibrates reduce triglycerides by approximately 40-
50% in HIV-infected patients with hypertriglyceridemia 
[109, 127, 128, 129], with larger reductions in those with 
higher baseline TG levels [126, 130]. These effects appear to 
be similar to the effect of statins [128] (see below) and in 
one study were superior to switching PI to NNRTI [109]. In 
studies fibrates appear to be well tolerated, with gastrointes-
tinal upset being the most frequently reported side effect. 
Proportions of patients achieving target goals vary, with one 
study reporting 70% achieving a target TG200mg/dL, but 
most others report much lower proportions ranging from 1-
40%  [98, 126, 131]. Despite these benefits, it is still unclear 
if reductions in triglyceride concentrations alone will be suf-
ficient to significantly alter overall cardiovascular risk in 
HIV-infected patients. 
Statins 
  HMG CoA reductase inhibitors, or “statins” have been 
shown to be an effective method of treating hypercholes-
terolemia in HIV-negative individuals and are also effective 
in HIV-infected individuals, reducing total cholesterol by 
approximately 30% and triglycerides by similar amounts 
[128, 130, 132, 133]. As with use of fibrates for hyper-
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C targets with statin use vary, with some studies reporting 
50-60% patients reaching NCEP targets [128, 130, 132], 
while others report far lower percentages [131, 134]. Interac-
tions between statins and antiretrovirals (ARVs) are very 
common. PIs inhibit the CYP3A4 metabolism of statins, and 
increase overall exposure to statins, in the case of simvas-
tatin by over 3000% [135]. This has led to concerns regard-
ing the potential for statin toxicity with PI use and for this 
reason simvastatin is contraindicated with concurrent PI use. 
However atorvastatin (at 10-80mg qd) and pravastatin (at 20-
80mg qd) are less affected by this interaction and have been 
extensively studied with PIs [109, 128, 130, 136]. Con-
versely, the NNRTI efavirenz induces hepatic metabolism of 
statins, leading to a marked reduction in the AUC for sim-
vastatin, pravastatin and atorvastatin [137]. The newer statin 
rosuvastatin is only marginally metabolised by the CYP3A4 
system, with most of the drug being excreted unchanged, and 
has been used to treat dyslipidaemia in HIV-infected patients 
[132]. Despite this, both lopinavir/ritonavir  [138, 139] and 
atazanavir/ritonavir [140] increase both the Cmax and AUC of 
rosuvastatin. This may be due to blockage of the OATP-1B1 
membrane transporter for rosuvastatin, of which ritonavir is 
a known inhibitor [138]. This transporter is involved in the 
hepatic uptake of rosuvastatin, therefore ritonavir inhibition 
may reduce the effect of rosuvastatin on lowering cholesterol 
despite inducing higher circulating concentrations of the 
drug [124].  
Ezetimibe 
  Ezetimibe, which blocks cholesterol absorption in the 
intestine and is metabolised independent of the CYP3A4 
pathway, appears to have minor effects in HAART-induced 
dyslipidemia as monotherapy [141]. However when added to 
pravastatin it allowed 62% of patients with hyperlipidemia to 
achieve a target LDL-C concentration of 130mg/dl [142]. 
Its effects seem confined to LDL-C reduction as effects on 
triglycerides in HAART-induced dyslipidemia appear minor 
[141, 142]. 
Niacin 
  Niacin has been investigated in two small studies, and 
appears to be well-tolerated, reducing TG levels by ap-
proximately 30% with a smaller effect on total cholesterol  
[143, 144]. A concern is the increase in insulin resistance 
seen in both studies. Given the concern over insulin resis-
tance and diabetes in HIVLD the role for routine use of nia-
cin in this setting is unclear. 
Combination Therapies 
  There are few data reporting the efficacy or safety of 
combination therapies in HIV-infected individuals. One open 
label study allowed the addition of pravastatin or fenofibrate 
to those who had failed to reach NCEP guidelines on either 
agent as monotherapy for 12 weeks [131]. Combination 
therapy was well tolerated and led to reductions in TG levels 
particularly, but only allowed 4% of patients to achieve 
combined NCEP guidelines. The increased risk of rhabdo-
myolysis in HIV-negative individuals from the combination 
of statins and fibrates [124] would advise their concurrent 
use in HIV positive patients only be undertaken with strict 
caution. 
CONCLUSION / FUTURE DIRECTIONS 
  As the ongoing roll-out of antiretroviral treatment pro-
grams in resource poor settings is continuing, use of older 
medications such as tNRTIs is common [145]. As a result 
dyslipidemia and lipodystrophy will continue to be major 
issues for many HAART treated patients for years to come 
[146]. The recent introduction of new medications with more 
lipid friendly profiles within existing classes such as darun-
avir (PI) [46], and etravirine (NNRTI) [147] will broaden the 
options available to clinicians. In addition, entirely new 
classes of drugs, such as integrase inhibitors (raltegravir) 
[148] and CCR5 inhibitors (maraviroc) [149] should allow 
more options both for antiretroviral-naïve patients starting 
therapy and those needing to switch therapies to avoid 
dyslipidaemia. Furthermore, the development of newer, se-
lective boosting agents to replace ritonavir that lack dyslipi-
daemia is continuing
4. Such advances could reduce the re-
quirement for ritonavir as a boosting agent, further reducing 
the potential for ARV to induce dyslipidemia. Despite early 
data showing much less effects on lipids with these new 
agents, long term safety data is required and clinicians will 
need to remain vigilant for treatment-related toxicities as 
HIV-infected individuals continue to live longer and healthier 
lives. 
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